Advanced in Cafe-Au-Lait Spots

David N. Cooper

Heath Park, 
Cardiff, WLS, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Cafe-Au-Lait Spots
Heath Park, 
Cardiff, WLS, GB 
OverviewLocationsClinical Research

Overview

David Cooper practices in Cardiff, United Kingdom. Mr. Cooper is rated as an Advanced expert by MediFind in the treatment of Cafe-Au-Lait Spots. His top areas of expertise are Chronic Pancreatitis, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Hereditary Pancreatitis.

His clinical research consists of co-authoring 292 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Cafe-Au-Lait Spots.

Gender
Male

Locations

Heath Park, Cardiff, WLS, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease
A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Other, Genetic
Study Phase: Phase 1/Phase 2
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

291 Total Publications

SMARCB1-related schwannomatosis and other SMARCB1-associated phenotypes: clinical spectrum and molecular pathogenesis.
SMARCB1-related schwannomatosis and other SMARCB1-associated phenotypes: clinical spectrum and molecular pathogenesis.
Journal: Familial cancer
Published: June 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cooper's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 52 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile